Wang G, et al. - This phase II study was conducted to evaluate the tolerability and safety of S-1 plus oxaliplatin (SOX) as adjuvant therapy after curative resection in Chinese patients with gastric cancer (GC). Adjuvant chemotherapy comprised of six to eight cycles of S-1 plus oxaliplatin. The treatment completion rate for six cycles was the primary end point of the trial. Safety, 1-year and 3-year of disease free survival (DFS) and overall survival (OS) were the secondary endpoints. On the basis of the data collected, it was concluded that adjuvant chemotherapy for GC with S-1 plus oxaliplatin was safe and feasible in Chinese patients.